As a result, accurate measurements of changes in EC50 was not possible in all patients, and pre- and postdose samples from RA patients were investigated for potential normalization of reduced magnitude of IL-6 response on days 15 and 43 (when IL-17 RO was high). This evidence concerns the gene IL17A and rheumatoid arthritis.